The Infectious Diseases Society of America offers category 1 CME credit for reviewing manuscripts. Only reviews received on time and judged satisfactory by the Editor(s) responsible for the particular manuscript will be eligible for CME credit. We only provide CME credit to reviewers if they request CME credit at the time they complete their review.
The features that contribute most importantly to the quality of manuscript reviews for the Journal include: adherence to reviewer guidelines, specificity and accuracy, completeness, usefulness of recommendations to both editors and authors, tone, internal consistency, and mindfulness of the needs of our readers and the medical community as a whole.
To prepare a high quality review, the reviewer should consider existing evidence when preparing his or her comments. The reviewer should place the current work in the context of existing evidence in the area, describe the unique contributions of the current work, and comment on any inconsistencies of the current work with previous research in your area.
You will be notified via email if your review of the assigned manuscript was completed on time and if it met our criteria for CME credit.
The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. IDSA designates each manuscript review for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians are eligible for up to 3 CME credits for each manuscript review, up to a total of 15 per year.
Through the manuscript peer review process for CID, JID, or OFID, you should be able to:
In compliance with ACCME's Standards for Commerical Support of Continuing Medical Education, anyone in a position to influence content is required to disclose any real or apparent conflicts of interest before participating in a CME-accredited educational activity. IDSA, in collaboration with CID and JID, identifies and resolves all conflicts of interest prior to manuscript reviews.
Sherwood L. Gorbach: Employee (part-time): Cubist Pharmaceuticals, Inc.; Advisory Board/Consultant/Stockholder: Cempra Pharmaceuticals, Seres Health
Michael Barza: Employee: Steward Carney Hospital, Tufts Medical Center; shareholder: Abbott Labs, Abbvie.
Sara Cosgrove: Employee: Johns Hopkins University School of Medicine' Advisory Board/Consultant: Novartis; Grants (through institution): Pfizer Grants for Learning and Change
Barbara Alexander: Employee: Duke University; Grants (through institution): Astellas, Charles River Labs, Pfizer, Scynexis, Viamet; Site investigator for clinical trial: Cubit, Virapharma
Neil Blacklow: Stockholder: BristolMyersSquibb
Donald Goldmann: Employee: Institute for Healthcare Improvement
Camilla Graham: Employee: Beth Israel Deaconess Medical Center, Up To Date
John R. Graybill: Nothing to disclose
A.W.Karchmer: Employee: Beth Israel Deaconess Medical Center; Advisory Board/Consultant: Debiopharma, Merck, Pfizer, Cubist; Stockholder: Optimer; Johnson and Johnson, Pfizer, E. Lilly, Arena Pharmaceuticals, Amgen, Gilead; Grants: Theravance
Jerry Klein: Employee: Boston University School of Medicine; Advisory Board/Consultant: Save the Children, GlaxoSmithKline Vaccines, Optimer
Robert Schooley: Employee: University of California, San Diego; Advisory Board/Consultant: Theraclone, Santaris, CytoDyn, Merck; Honoraria: AASLD, University of Singapore; Grants: Boehringer-Ingelheim, Merck; Grants (through institution): Gilead Sciences, Globelmmune, Monogram Biosciences
Cynthia Sears: Grants: Merieux Institute
Lucy Tompkins: Employee: Stanford University; Advisory Board/Consultant (and stockholder): iSense, Inc.
Chris Wanke: Employee: Pratt Physician Group; Advisory Board/Consultant: Pfizer, Cubist; Clinical Trial: GlaxoSmithKline; Patent: Parr
Ann Arvin: Consultant: GlaxoSmithKline, Novartis, Merck, Vaxart
Marcel Behr: Nothing to disclose
Raymund Chung: Grants: Gilead, Mass Biologics, Vertex; Consultant: Abbvie, Idenix
Peter Densen: Nothing to disclose
Joseph Kovacs: Nothing to disclose
Daniel Kuritzkes: Grant: Gilead, Merck; Consultant: Bristol-Myers Squibb, Celera, Gilead, GlaxoSmithKline, InnaVirVax, Koronis, Boehrunger-Ingelheim, Merck, Tobira, ViiV; Honoraria: Roche, Gilead and ViiV
Stuart Levitz: Nothing to disclose
William Schaffner: Consultant: Sanofi-Pasteur, Dynavax, Pfizer; Data Safety Monitoring Board: Merck
Jane Schwebke: Grants: Hologic/GenProbe, Akesis, BD Diagnostics, Cepheid, Quidel, Symbiomix, StarPharma; Consultant: Akesis, Hologic/GenProbe
Peter Weller: Advisory Board: GlaxoSmithKline
Richard Whitley: Board of Directors: Gilead Sciences; Honoraria: Roche-IRIS Expert Panel; Consulting: N&N Pharmaceuticals, Merck Data Safety and Monitoring Board, GlaxoSmithKline-Watermark Data Safety Monitoring Board
Michael Hughes: Data Safety and Monitoring Board (paid): Boehringer-Ingelhiem, Medicines Development, Pfizer, Tibotec
Sarah Walker: Grant:ViiV/GlaxoSmithKline; Speaker Fee: Gilead Sciences
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2014 Infectious Diseases Society of America